Imugene’s products are likely to sell into large and growing markets. In the case of the pig
and chicken products a key driver is the move away from medicated feeds while the flea vaccine
project may be a beneficiary of the large sums of money people lavish on their companion
animals.
�� We value Imugene at 52 cents per fully diluted share base case, and $1.70 per fully diluted
share on a ‘Speculative If Everything Works’ case. Our share price target of $1.11 is a midpoint
of these two figures.
thirty mill deal clinched by aussie biotech, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
